
Maurizio Rupolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1404749/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	miR-335-laden B Cell-Derived Extracellular Vesicles Promote SOX4-Dependent Apoptosis in Human Multiple Myeloma Cells. Journal of Personalized Medicine, 2021, 11, 1240.	2.5	2
2	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 378-384.	1.4	3
3	Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplantation, 2018, 53, 228-230.	2.4	7
4	EP-1246: Radiotherapy after autologous stem cell transplant in recurrent or refractory hodgkin's lymphoma. Radiotherapy and Oncology, 2018, 127, S689.	0.6	0
5	Post-transplantation long-term outcomes in 43 HIV-positive patients affected by high-risk or relapsed lymphoma Journal of Clinical Oncology, 2017, 35, 121-121.	1.6	0
6	Primary Non-Hodgkin's Lymphoma of the Vulva. Medicine (United States), 2016, 95, e3041.	1.0	19
7	Postautologous stem cell transplantation long-term outcomes in 26 HIV-positive patients affected by relapsed/refractory lymphoma. Aids, 2015, 29, 2303-2308.	2.2	8
8	γ-Herpesvirus Load as Surrogate Marker of Early Death in HIV-1 Lymphoma Patients Submitted to High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation. PLoS ONE, 2015, 10, e0116887.	2.5	5
9	Autograft HIV-DNA Load Predicts HIV-1 Peripheral Reservoir After Stem Cell Transplantation for AIDS-Related Lymphoma Patients. AIDS Research and Human Retroviruses, 2015, 31, 150-159.	1.1	6
10	Post-transplantation long-term events in a cohort of HIV-positive patients affected by relapsed/refractory lymphoma Journal of Clinical Oncology, 2015, 33, 7031-7031.	1.6	1
11	Which tools may help physicians in female fertility prediction after autologous bone marrow transplantation for lymphoma? A pilot study. Journal of Chemotherapy, 2014, 26, 293-299.	1.5	6
12	P.16.6 AMINOPYRINE BREATH TEST AS A DIAGNOSTIC TOOL TO EVALUATE HEPATIC FUNCTIONAL RESERVE IN NEOPLASTIC PATIENTS RECEIVING HIGH DOSE CHEMOTHERAPY. Digestive and Liver Disease, 2014, 46, S116.	0.9	0
13	Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology, 2014, 53, 381-382.	1.9	21
14	The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S671.	0.8	0
15	Long term cryopreservation in 5% <scp>DMSO</scp> maintains unchanged <scp>CD</scp> 34 ⁺ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation. Vox Sanguinis, 2013, 105, 77-80.	1.5	23
16	Nutrition in oncologic patients during antiblastic treatment. Frontiers in Bioscience - Landmark, 2013, 18, 120.	3.0	2
17	Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1438-1443.	1.7	4
18	Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1419-1429.	1.7	6

MAURIZIO RUPOLO

#	Article	IF	CITATIONS
19	Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision. International Journal of Immunopathology and Pharmacology, 2012, 25, 21-32.	2.1	0
20	<i>Mycobacterium tuberculosis:</i> An Infection We Should Suspect in Bone Marrow Transplantation. Journal of Chemotherapy, 2011, 23, 312-313.	1.5	2
21	A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. Vox Sanguinis, 2010, 98, 172-180.	1.5	13
22	Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIVâ€Infected versus HIVâ€Uninfected Patients with Relapsed or Refractory Lymphoma. Clinical Infectious Diseases, 2010, 50, 1672-1679.	5.8	45
23	Predictive Value of HIV Type 1 DNA Levels on Overall Survival in HIV-Related Lymphoma Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT). AIDS Research and Human Retroviruses, 2010, 26, 245-251.	1.1	11
24	Interferon-alpha for maintenance of follicular lymphoma. The Cochrane Library, 2010, , CD004629.	2.8	15
25	P101 The family burden of elderly cancer patient. Preliminary results. Critical Reviews in Oncology/Hematology, 2009, 72, S54.	4.4	Ο
26	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood, 2009, 114, 1306-1313.	1.4	130
27	Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor. Vox Sanguinis, 2008, 94, 342-350.	1.5	5
28	Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjogren's Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma. Open Rheumatology Journal, 2008, 2, 38-43.	0.2	60
29	Maintenance immunotherapy after autologous bone marrow transplantation (ABMT) in relapsed follicular (R-FL) and mantle cell (R-MC) lymphomas (NHL). A monoinstitutional experience. Journal of Clinical Oncology, 2008, 26, 18012-18012.	1.6	Ο
30	R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL). Journal of Clinical Oncology, 2007, 25, 8036-8036.	1.6	1
31	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. Journal of Translational Medicine, 2006, 4, 11.	4.4	9
32	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. Journal of Cellular Physiology, 2006, 207, 354-363.	4.1	49
33	Effects on virological and immunological parameters during CD34 mobilization in HIV patients with lymphoma. American Journal of Hematology, 2006, 81, 800-802.	4.1	6
34	Metastatic Angiosarcoma of the Kidney: A Case Report with Treatment Approach and Review of the Literature. Journal of Chemotherapy, 2006, 18, 221-224.	1.5	16
35	Quantitative PCR of bone marrow BCL2/lgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood, 2005, 105, 3428-3433.	1.4	102
36	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. Journal of Immunological Methods, 2005, 305, 20-32.	1.4	17

MAURIZIO RUPOLO

#	Article	IF	CITATIONS
37	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. Journal of Cellular Physiology, 2005, 204, 113-123.	4.1	30
38	Is high-dose chemotherapy with peripheral stem cell rescue a suitable option for elderly patients affected by aggressive non-Hodgkin's lymphoma?. Annals of Oncology, 2005, 16, 837-838.	1.2	2
39	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. International Journal of Oncology, 2005, 26, 945.	3.3	3
40	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2005, 6, 251-252.	1.4	3
41	Lymphangioleiomyomatosis: A Case Report and Review of the Literature. Tumori, 2004, 90, 528-531.	1.1	7
42	Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. Aids, 2004, 18, 1859-1861.	2.2	2
43	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. British Journal of Haematology, 2004, 125, 203-212.	2.5	26
44	Analysis of IgVH gene mutations in BÂcell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42.	2.5	54
45	Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2004, 5, 123-126.	2.1	9
46	Immunophenotypic clustering of B-Cell chronic lymphocytic leukemia (B-CLL) reveals a good prognosis disease subset characterized by the coordinated over-expression of CD62L, CD54, CD49c, CD25 And CD55. Journal of Clinical Oncology, 2004, 22, 6567-6567.	1.6	1
47	Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. Leukemia, 2003, 17, 1433-1436.	7.2	22
48	High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy. Journal of Clinical Oncology, 2003, 21, 4423-4427.	1.6	144
49	5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood, 2003, 101, 4644-4646.	1.4	78
50	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood, 2002, 99, 856-862.	1.4	155
51	CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Experimental Hematology, 2002, 30, 1283-1292.	0.4	31
52	Metastatic Angiosarcoma of the Spleen. A Case Report and Treatment Approach. Tumori, 2001, 87, 439-443.	1.1	13
53	In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human γδ+ T-cell malignancies. British Journal of Haematology, 2000, 110, 188-196.	2.5	30
54	Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus–associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor–producing cells that occur mainly in type II cryoglobulinemia. Blood, 2000, 96, 3578-3584.	1.4	205

MAURIZIO RUPOLO

#	Article	IF	CITATIONS
55	Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study. Therapeutic Drug Monitoring, 2000, 22, 295-301.	2.0	60
56	Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma. British Journal of Cancer, 1998, 77, 2032-2035.	6.4	71
57	Hodgkin's disease: A disorder of dysregulated cellular cross-talk. Biotherapy (Dordrecht,) Tj ETQq1 1 0.784314	4 rgBT /O\ 0 . 7	verlock 10 T
58	Differential expression of the RET gene in human acute myeloid leukemia. Annals of Hematology, 1998, 77, 207-210.	1.8	12
59	Active protection from chemotherapy toxicity1Supported by AIRC and CNR.1. Critical Reviews in Oncology/Hematology, 1998, 27, 125-127.	4.4	1
60	Vimentin and proliferating cell nuclear antigen (PCNA) expression in node-negative breast carcinomas and their correlations with pathologic variables and prognosis. Breast, 1995, 4, 175-178.	2.2	1
61	The Extent of Surgery for Thyroid Medullary Cancer. Tumori, 1994, 80, 427-432.	1.1	15
62	Thyroid Cancer in Children and Adolescents. Tumori, 1994, 80, 257-262.	1.1	58